12/26
06:51 am
tvtx
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday [Yahoo! Finance]
Low
Report
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday [Yahoo! Finance]
12/25
07:00 pm
tvtx
Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? [Yahoo! Finance]
Low
Report
Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? [Yahoo! Finance]
12/25
07:00 pm
tvtx
Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom [Yahoo! Finance]
Low
Report
Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom [Yahoo! Finance]
12/25
07:00 pm
tvtx
Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI [Yahoo! Finance]
12/11
05:00 pm
tvtx
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/29
03:35 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at
Wall St
Low
Report
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at
Wall St
11/28
08:00 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
11/26
08:18 am
tvtx
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]
Low
Report
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]
11/26
07:22 am
tvtx
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]
Low
Report
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]
11/19
03:00 pm
tvtx
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]
Low
Report
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]
11/14
07:54 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/10
05:00 pm
tvtx
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/6
11:29 am
tvtx
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]
Neutral
Report
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]
11/6
11:00 am
tvtx
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Low
Report
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
11/4
05:23 pm
tvtx
Travere Therapeutics to Participate at Upcoming Investor Conferences
Low
Report
Travere Therapeutics to Participate at Upcoming Investor Conferences
11/4
11:54 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Piper Sandler from $26.00 to $35.00. They now have a "neutral" rating on the stock.
Low
Report
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Piper Sandler from $26.00 to $35.00. They now have a "neutral" rating on the stock.
11/1
10:33 pm
tvtx
Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat [Yahoo! Finance]
Low
Report
Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat [Yahoo! Finance]
11/1
03:11 pm
tvtx
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook [Yahoo! Finance]
11/1
08:33 am
tvtx
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone [Yahoo! Finance]
10/31
11:27 pm
tvtx
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives [Yahoo! Finance]
10/31
02:43 pm
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at TD Cowen from $30.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at TD Cowen from $30.00 to $40.00. They now have a "buy" rating on the stock.
10/31
11:20 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Citigroup Inc. from $34.00 to $48.00. They now have a "buy" rating on the stock.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Citigroup Inc. from $34.00 to $48.00. They now have a "buy" rating on the stock.
10/31
11:03 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
10/30
11:33 pm
tvtx
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
10/30
04:08 pm
tvtx
Travere Therapeutics Non-GAAP EPS of $0.59 beats by $0.68, revenue of $164.9M beats by $58.81M [Seeking Alpha]
Medium
Report
Travere Therapeutics Non-GAAP EPS of $0.59 beats by $0.68, revenue of $164.9M beats by $58.81M [Seeking Alpha]